Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) President Cam Gallagher sold 10,000 shares of the firm's stock in a transaction dated Thursday, January 5th. The stock was sold at an average price of $21.02, for a total value of $210,200.00. Following the transaction, the president now owns 362,011 shares of the company's stock, valued at $7,609,471.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Cam Gallagher also recently made the following trade(s):
Get Zentalis Pharmaceuticals alerts:- On Tuesday, November 15th, Cam Gallagher sold 12,500 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $22.77, for a total value of $284,625.00.
- On Monday, November 7th, Cam Gallagher sold 12,500 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $23.67, for a total value of $295,875.00.
- On Monday, October 17th, Cam Gallagher sold 12,500 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $23.51, for a total value of $293,875.00.
Zentalis Pharmaceuticals Stock Performance
Shares of Zentalis Pharmaceuticals stock opened at $21.21 on Friday. Zentalis Pharmaceuticals, Inc. has a 52 week low of $17.33 and a 52 week high of $75.66. The stock has a 50 day moving average price of $20.87 and a two-hundred day moving average price of $24.45. The stock has a market capitalization of $1.21 billion, a PE ratio of -4.49 and a beta of 1.77.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on ZNTL shares. Oppenheimer decreased their target price on Zentalis Pharmaceuticals from $80.00 to $50.00 and set an "outperform" rating for the company in a research note on Thursday, November 10th. Guggenheim decreased their target price on Zentalis Pharmaceuticals from $55.00 to $28.00 and set a "buy" rating for the company in a research note on Friday, November 11th. SVB Leerink decreased their target price on Zentalis Pharmaceuticals from $42.00 to $27.00 and set an "outperform" rating for the company in a research note on Thursday, November 10th. Wedbush decreased their target price on Zentalis Pharmaceuticals from $51.00 to $32.00 and set an "outperform" rating for the company in a research note on Monday, November 14th. Finally, UBS Group decreased their target price on Zentalis Pharmaceuticals to $52.00 in a research note on Monday, November 21st. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $46.56.Institutional Investors Weigh In On Zentalis Pharmaceuticals
Hedge funds have recently added to or reduced their stakes in the company. Assetmark Inc. boosted its position in shares of Zentalis Pharmaceuticals by 337.3% during the second quarter. Assetmark Inc. now owns 1,054 shares of the company's stock valued at $30,000 after buying an additional 813 shares during the last quarter. Captrust Financial Advisors boosted its position in shares of Zentalis Pharmaceuticals by 15,160.0% during the first quarter. Captrust Financial Advisors now owns 763 shares of the company's stock valued at $35,000 after buying an additional 758 shares during the last quarter. Great West Life Assurance Co. Can purchased a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $48,000. Point72 Hong Kong Ltd purchased a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $59,000. Finally, Metropolitan Life Insurance Co NY boosted its position in shares of Zentalis Pharmaceuticals by 24.1% during the third quarter. Metropolitan Life Insurance Co NY now owns 2,828 shares of the company's stock valued at $61,000 after buying an additional 550 shares during the last quarter.
Zentalis Pharmaceuticals Company Profile
(Get Rating)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Recommended Stories
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.